• 제목/요약/키워드: 고지혈증 치료제

Search Result 42, Processing Time 0.027 seconds

동맥경화질환 예방치료제의 개발 전략

  • 김영국
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2001.04a
    • /
    • pp.45-59
    • /
    • 2001
  • 최근 급속한 산업화와 경제발전으로 인해 소득수준이 향상되면서, 고단백질 및 고지방질 식품의 섭취 및 운동부족으로 인한 성인병, 특히 비만증, 고지혈증, 당뇨병 및 심장순환기계질환이 급속히 증가되어 사회문제로 대두되었고, 한국을 포함한 선진각국의 고지혈증 및 심장순환기계질환의 발병빈도가 여전히 증가추세에 있다. 보건위생의 여건이 좋아지면서 전염성질환이 줄어들었으나, 심장 순환기 질환의 발병률은 계속 증가추세에 있고, 순환기질환은 고지혈증에 의하여 발병되며 이 질환의 사망률은 전체 사망률 중 상위를 차지하고 있다. 인간은 고지혈증에 의한 동맥경화로 인한 사망률은 전체 사망률 중에서 상위를 차지하고 있으며, 그에 따른 의약품의 개발이 요구되고 있고, 현재 임상적으로 사용되고 있는 고지혈증 치료제로는 체내의 cholesterol 생합성 저해제가 있으나, 보다 제한사항이 없고, 작용기작이 확실하며 부작용이 적은 새로운 고치혈증 치료제의 개발이 요구되고 있다. 콜레스테롤은 세포막의 구성과 스테로이드 호르몬의 전구체로서 생체를 구성하는데 필수적인 요소이지만 과다하게 공급되었을 경우 동맥경화와 같은 심혈관계 질환을 유발할 수 있다. 체내에 콜레스테롤의 공급은 체외 음식물로부터 섭취하는 방법과 체내에서 생합성에 의해 공급되는 방법이 있는데, 서로 유기적인 보완관계를 유지하면서 필요한 콜레스테롤의 양을 유지한다. 그러나, 현대인의 식생활이 급격한 서구화로 체외로부터 필요량 이상으로 콜레스테롤이 유입되어 각종 성인병 발명의 상승 요인이 되고 있다.

  • PDF

Biodegradation of Blood Lipid Lower Agents (BLLAs) in Biological Activated Carbon (BAC) Process (BAC 공정에서의 고지혈증 치료제 생물분해 특성)

  • Yoom, Hoon-Sik;Son, Hee-Jong;Ryu, Dong-Choon;Yoo, Pyung-Jong
    • Journal of Korean Society of Environmental Engineers
    • /
    • v.39 no.3
    • /
    • pp.124-131
    • /
    • 2017
  • In this study, We investigated the effects of water temperature and empty bed contact time (EBCT) on the biodegradability of 8 blood lipid lower agents (BLLAs) in biological activated carbon (BAC) process. Experiments were conducted at three water temperatures ($8^{\circ}C$, $16^{\circ}C$ and $24^{\circ}C$) and three EBCTs (5 min, 10 min and 15 min). Increasing water temperature and EBCT increased the biodegradation efficiency of BLLAs in BAC process. Simvastatin and fenofibrate were the highest biodegradation efficiency, but atorvastatin and clofibric acid were the lowest. The kinetic analysis suggested a pseudo-first-order reaction model for biodegradation of 8 BLLAs at various water temperatures and EBCTs. The pseudo-first-order biodegradation rate constants ($k_{bio}$) of clofibric acid and atorvastatin were $0.0075min^{-1}$ and $0.0122min^{-1}$ at $8^{\circ}C$, and were $0.0540min^{-1}$ and $0.0866min^{-1}$ at $24^{\circ}C$, respectively. By increasing the water temperature from $8^{\circ}C$ to $24^{\circ}C$, the biodegradation rate constants ($k_{bio}$) were increased 7.1~7.2 times.

The Impact of Direct-to-Consumer Advertising of Prescription Medications on Healthy Lifestyle (전문의약품 소비자광고가 생활습관 변화에 미치는 영향에 대한 연구)

  • Yang, Hae-Kyung
    • Journal of the Korean Home Economics Association
    • /
    • v.50 no.4
    • /
    • pp.103-113
    • /
    • 2012
  • In the U.S. where Direct-to-Consumer Advertising (DTCA) of prescription medications is permitted, spending on DTCA has been accelerating. As a result, it has been an issue of intense public policy attention regarding whether DTCA is beneficial to the public by promoting a healthy lifestyle. Most of the literature concerning DTCA focuses on its impact on demand and empirical evidence regarding its impact on health-related behavior is scant. This study uses a database of DTCAs for high blood cholesterol, hypertension, diabetes, and overweight treatment medications that have appeared in nationally circulated U.S. consumer magazines during 2000 to 2004 and the Simmons National Consumer Survey in order to compute the level of individual advertising exposure and examines whether those who are exposed to DTCA are more likely to engage in regular exercise and diet control. The study finds evidence that for those with chronic conditions, greater exposure to DTCA leads to less exercise but more diet control. By therapeutic class level, exposure to DTCA leads to less exercise for those with hypertension and who are overweight, whereas those with high blood cholesterol are more likely to engage in regular exercise. Looking into differential responses by socioeconomic status, those with less education are more likely to engage in exercise after being exposed to DTCA. The results imply that the effects of DTCA vary by therapeutic class. In order to enhance the benefits of DTCA, it is important to closely monitor the messages in DTCA and require it to include messages that promote lifestyle change should it be a part of the treatment.

Evaluation of short-term Hypolipidemic Effect and Safety of Simvastatin($Zocor^{(R)}$) in Patients with Hyperlipidemia (고콜레스테롤혈증 환자에서 Simvastatin($Zocor^{(R)}$) 단기 투여후 효과와 안정성 평가)

  • Kim, Min-Kyoung;Park, Yong-Ho;Park, Jong-Sun;Shin, Dong-Gu;Kim, Young-Jo;Kim, Gi-Sik
    • Journal of Yeungnam Medical Science
    • /
    • v.20 no.2
    • /
    • pp.152-159
    • /
    • 2003
  • Background : Hyperlipidemia is the one of the major risk factors causing the atherosclerosis of coronary arteries. Treatment of hyperlipidemia with drugs has been confirmed the effects of therapy showing a decreased incidence of coronary artery disease. Simvastatin is a new drug of HMG-CoA reductase inhibitors and the short-term hypolipidemic effects and safety of simvastatin is evaluated in patients with hyperlipidemia. Methods: We studied 63 patients (39 males and 24 females, mean age 58) for 12 weeks whose plasma levels of total cholesterol were higher than 240 mg/dL or higher than 220 mg/dL with ischemic heart disease. Simvastatin was administered 20 mg/day and measured lipid profile at 12 week interval. Result: 1) Simvastatin significantly reduced the level of the plasma total cholesterol(-29.3%), LDL-cholesterol(-36.9%) and triglyceride(-13%)(p<0.05) but the level of HDL-cholesterol was not changed after 12 weeks simvastatin therapy. 2) the clinical symptoms and laboratory examination before and after simvastatin treatment showed no particular abnormal findings in short term follow up. Conclusion: These results suggested that short-term simvastatin therapy in patients with hyperlipidemia seeems to be very effective and safe.

  • PDF

특집_의료진과 함께 한 제 12회 성인당뇨캠프 - 강의노트-체육학 교수가 전한 당뇨정보 - 당뇨병과 운동

  • 사단법인한국당뇨협회
    • The Monthly Diabetes
    • /
    • s.239
    • /
    • pp.26-28
    • /
    • 2009
  • 당뇨병의 치료와 관리에 있어 운동은 보약과 같다. 혈당을 내려주고 체중을 조절해줘 비만을 방지해주며 고혈압, 고지혈증, 심장병, 골다골증 등을 예방해주는 효과가 있다. 운동은 당뇨병 치료로서 전부가 아니라 의학적인 차원에서도 반드시 필요하다.

  • PDF

Peroxisome proliferator-activated receptor $\alpha$(PPAR$\alpha$) and its clinical significance

  • 윤미정
    • The Zoological Society Korea : Newsletter
    • /
    • v.18 no.2
    • /
    • pp.6-11
    • /
    • 2001
  • Peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$)에 대한 본격적인 연구는 고지혈증 치료제인 fibrate류의 약물들이 PPAR$\alpha$ activator로 작용한다는 사실이 밝혀짐으로써 크게 증대되었다. PPAR$\alpha$는 fibrate를 포함한 다양한 종류의 peroxisome proiferator (PP)에 의해 활성화되는데 이들을 쥐에 단기간 투여할 경우 간의 peroxisome수와 지 방산 산화효소의 유전자발현이 증가되고 장기간 투여 할 경우 간암을 발생시키지만, fibrate류의 약물들을 고지혈증 환자에게 투여 할 경우 간암을 발생시키지 않으므로써 PP에 대한 반응성에 있어서 species difference를 나타낸다 PPAR$\alpha$는 핵에 존재하는 orphan receptor로서 PP에 의해 활성화되어 9-cis-retinoic acid receptor(RXR)와 heterodimer를 이룬 후 target gene들의 upstream에 있는 peroxisome proliferator response element (PPRE)에 결합하여 target gene들의 발현을 조절한다. 지금까지 연구된 PPAR$\alpha$의 target gene들은 모두 lipid와 lipoprotein 대사를 조절하는 것으로 알려져 있으며, 이러 한 결과들을 기초로 lipid 대사 및 energy balance와 관련된 질병들 - 동맥경화증, 관상동맥질환, 비만, 제 2형 당뇨병 등에서 PPAR$\alpha$의 역할이 집중적으로 연구되고 있다. PPAR$\alpha$가 활성화되면 lipoprotein lipase와 HDL이 증가되고 apo C-III가 감소됨으로써 동맥경화증에 대한 예방적 기능을 나타내고, 몸무게를 감소시킴으로써 비만을 방지할 수 있으며, 인슐린 감수성을 증가시켜 제 2형 당뇨병의 치료효과를 가지는 것으로 보인다. 그러나 PPAR$\alpha$-null mouse에서는 이러한 효과들이 나타나지 않는 것으로 보아 이들 질병에서 PPAR$\alpha$가 중요한 역할을 하는 것으로 생각된다.

  • PDF

The effect of swimming plus hypolipidemic agent on obesity (비만에 대한 고지혈증 치료제와 수영운동의 병합처방의 효과)

  • Jeong, Sun-Hyo
    • Journal of the Korean Applied Science and Technology
    • /
    • v.36 no.1
    • /
    • pp.34-46
    • /
    • 2019
  • Obesity is frequently associated with metabolic disease. This study showed whether fenofibrate, a hypolipidemic agent, swimming and swimming combined with fenofibrate (: combination) regulate obesity, and whether combination is more effective than fenofibrate on regulation of obesity in high-fat diet-fed mice for 8 weeks. Both fenofibrate and swimming decreased obesity-associated factors such as body weight, adipose tissue mass, serum lipid levels and adipoctye size, compared with control mice. When mice were concomitantly treated with fenofibrate and swimming, combination reduced further the inhibitory effects on obesity-associated factors, compared with fenofibrate. Both fenofibrate, swimming and combination decreased serum glucose levels, compared with control mice. The evidence is presented herein that combination were effective to control obesity and serum glucose levels, suggesting that swimming combined with fenofibrate might contribute to inhibition of high-fat diet fed-induced metabolic syndrome.

Synthesis of trans-(3R,5S)-Atorvastatin Ca and Curative Effect on Hyperlipidemia Induced by a High-Fat Diet in Rats (trans-(3R,5S)-Atorvastatin Ca의 합성 및 Rat에서 고지방식이로 유도된 고지혈증 치료효과)

  • Choi, Won-Sik;Nam, Seok-Woo;Lee, Gyung-Rak
    • Journal of the Korea Academia-Industrial cooperation Society
    • /
    • v.12 no.11
    • /
    • pp.4940-4950
    • /
    • 2011
  • cis-(3R,5R)-Atorvastatin Ca (1) used for hyperlipidemia have four stereomers. However, It is very difficult to prepare stereoselective stereomers. In this paper, the reduction of 3,5-diketo atorvastatin ester (3) was performed using $Me_4NHB(OAc)_3$ in acetic acid as a reductant and showed excellent stereoselectivity in the double reduction of 3,5-diketo atorvastatin ester (3). As a result, reduction of compound 3 by $Me_4NHB(OAc)_3$ was purely obtained with cis-(3R,5R)-atorvastatin ester (4) of 1.5% and trans-(3R,5S)-atorvastatin ester (5) of 98.5%. Also, cis-(3R,5R)-atorvastatin Ca (1) and trans-(3R,5S)-atorvastatin Ca (7) were used to determine efficacy in the treatment of liver damage and hyperlipidemia induced by a high-fat diet in rats and to study the performance of the January 2010 experient was conducted. As a result, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), and triglyceride (TG) levels of compound 1 and 7 groups were $93.0{\pm}0.5$, $43.5{\pm}0.8$, $40.4{\pm}1.4$, $45.6{\pm}0.9\;mg/d{\ell}$ and $110.0{\pm}0.7$, $33.3{\pm}0.6$, $65.8{\pm}1.9$, $54.8{\pm}1.2\;mg/d{\ell}$, respectively. Atherogenic index (AI) and cardiac risk factor (CRF) in compound 1 and 7 were $1.14{\pm}0.05$, $2.14{\pm}0.05$ and $2.31{\pm}0.06$, $3.31{\pm}0.06$, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were $51.9{\pm}4.6$, $16.0{\pm}2.1\;IU/{\ell}$ and $75.8{\pm}4.4$, $35.1{\pm}9.7\;IU/{\ell}$. Taken together, while compound 1 treat against high-fat diet-induced hyperlipidemia by attenuating hepatic lipid depots and reducing oxidative stress, compound 7 group had a low curative effect on hyperlipidemia induced by a high-fat diet in rats. These findings suggest that new method about synthesis of stereoselective stereomers and indicate that it may consider using in a clinical trial.

비만의 약물요법에 대한 최신 지견

  • 이선영
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2001.04a
    • /
    • pp.3-30
    • /
    • 2001
  • 비만은 고혈압, 제2형 당뇨병, 지방간, 고지혈증, 퇴행성관절염, 일부 암성 질환 등 다양한 만성 퇴행성 질환들을 유발할 수 있으므로 비만을 하나의 질환으로 인식하고 치료할 필요가 있다. 비만은 식사요법, 운동요법과 행동수정요법을 병행해야 최상의 치료효과를 거둘 수 있다고 알려져 왔지만, 비만 치료가 끝나고 4년 후에 빠진 체중의 절반만이라도 다시 늘지 않고 유지하고 있는 사람은 10-30%에 불과하다. 그러나 비만 문제가 중요하고 현재까지의 치료방법이 성공적이지 못함에도 불구하고 비만의 약물 치료의 적절성에 대해서는 논란이 있다. 그러나 최근 비만의 약물 치료에 대해 재평가가 이루어지고 있으며, 식사, 운동, 행동요법과 약물치료의 병합 요법이 효과가 있음을 입증하는 연구결과들이 보고되고 있다. 여기에서는 비만증의 진단기준과 치료원칙을 간단히 설명하고 비만증의 약물요법을 위주로 살펴보도록 하겠다.

  • PDF

The Effect of 3-(4-hydroxyl -33,53-dimethoxyphenyl)propionic Acid in Chinese Cabbage Kimchi on Lowering Hypercholesterolemia (배추김치의 활성성분인 3-(4-hydroxyl-33,53-dimethoxyphenyl)propionic acid의 고지혈증 치료 효과)

  • 김현주;권명자;서정민;김재곤;송수희;서홍석;송영옥
    • Journal of the Korean Society of Food Science and Nutrition
    • /
    • v.33 no.1
    • /
    • pp.52-58
    • /
    • 2004
  • The active principle responsible for lipid lowering in Chinese cabbage kimchi, 3-(4-hydroxyl-3'5'-dimethoxyphenyl)propionic acid, of molecular weight 226, was chemically synthesized and then used for the treatment of hypercholesterolemia in male New Zealand white rabbit. Hypercholesterolemia in rabbits were induced by feeding 0.5% cholesterol added chow diet for 5 weeks. Each experimental group has four rabbits in it. for the 1st experiment,3-(4-hydroxyl-3'5'-dimethoxyphenyl)propionic acid or simvastatin was injected to the ear vein of rabbit every other day for 16 days (2 mg/3 kg/2 days) while normal chow diet was provided. Blood was drawn every 4th day. For the 2nd experiment, all the experimental condition was same as the 1st trial except 0.5% cholesterol diet was provided while 16 days. Plasma cholesterol level was decreased when cholesterol in the diet was removed. Decreased in cholesterol in kimchi and simvastatin groups were 18.65 and 29.67%, respectively compared to the control when the normal diet was given, and cholesterol increase was inhibited by 33.79 and 21.81% for kimchi and simvastatin groups, respectively, when 0.5% cholesterol diet was provided. The drop in LDL-C level by the active principle of kimchi and simvastatin was not significant when normal diet was given, however the changes was significant (p<0.05), approximately 130% decrease, when 0.5% cholesterol diet was given. The 105% and 62% decreased in triglyceride concentration were observed from 0.5% cholesterol diet fed kimchi and simvastatin groups respectively HDL cholesterol levels in experimental groups were not changed significantly from the both trials. The HMG-CoA reductase activity of kimchi and simvastatin groups were found to be higher than that of control to compensate the hypercholesterolemic condition induced by 0.5% cholesterol diet in these groups. In conclusion, diet is an important factor to control the hypercholesterolemia besides drug treatment. 3-(4-hydroxyl-3'5'-dimethoxyphenyl)propionic acid that is the active principle in Chinese cabbage kimchi seems a beneficial to the hypercholesterolemia and its effect is comparable to that of simvastatin.